




Don't Rash the Diagnosis!

Learning objectives:

- Diagnose Stevens-Johnson-Toxic-Epidermal-Necrolysis Spectrum with its multi-mucosal and multi-organ involvement.
- 2. Recognize the importance of multidisciplinary care for patients with Stevens-Johnson-Toxic-Epidermal-Necrolysis Spectrum.

Case Presentation

A 64-year-old man presents with a onemonth history of rash. Significant past medical history includes alcohol use disorder, congestive heart failure and chronic renal insufficiency.



His dermatitis then significantly worsened, extending to 90% body surface area. He had painful erythroderma over 90% body surface area with superficial scaling and sloughing, including on the palms and soles. Nikolsky's sign was positive.



The dermatitis did not resolve so he subsequently presented to his local emergency department twice and received two courses of cephalexin.

Investigations & Initial Management

- Skin biopsy was repeated. Working diagnosis was erythrodermic psoriasis vs Stevens-Johnson-Toxic-Epidermal-Necrolysis Spectrum (SJS/TEN).
- The patient received supportive management including intravenous fluids, antibiotics for presumed secondary bacterial infection, and temperature re-warming methods.
- Dermatology was consulted. Based on the painful erosions and mucositis present, there was a high suspicion for SJS/TEN. His treatment expanded to include clobetasol cream, wound care with non adherent dressing, methylprednisolone, cyclosporine, guselkumab and etanercept.
- The Ophthalmology team was also consulted and noted cicatrizing conjunctivitis.
- Skin biopsy showed extensive ulceration and necrosis with complete loss of epidermis and necrotic keratinocytes. SJS/TEN was confirmed and suspected to be secondary to cephalexin. His risk of mortality was estimated to be > 90% based on SCORTEN of 5¹.

SCORTEN

Scoring Criteria (1 point each)

actor Criteria	
> 40 years	
Rate > 120 bpm	
/Hematologic Malignancy Present	
urface Area Involved > 10%	
Urea/BUN > 28 mg/dL (> 10 mmol/l	∟)
Bicarbonate < 20 mEq/L (< 20 mmol/	′ L)
Glucose > 252 mg/dL (> 14 mmol	/L)
urface Area Involved > 10% Urea/BUN > 28 mg/dL (> 10 mmol/l Bicarbonate < 20 mEq/L (< 20 mmol/	′L)

Mortality Risk by SCORTEN Score

SCORTEN Score	Predicted Mortality Rate
0-1	3.2%
2	12.1%
3	35.8%
4	58.3%
5	90.0%
≥ 6	> 90%

Figure 1: SCORTEN (Score for Toxic Epidermal Necrolysis) severity-of-illness scale for SJS/TEN.

Discussion & Conclusion

Multidisciplinary discussions between Internal Medicine, Dermatology, Ophthalmology, Critical Care and the Burn Unit at a quaternary care center were necessary to guide treatment as the patient developed sepsis from Raoultella bacteremia, worsening hypothermia and multi-organ failure secondary to lack of epidermis and persistent inflammation. Despite treatment, the patient had worsening liver failure, renal failure and heart failure, leading to anasarca and severe pulmonary edema requiring oxygen delivery via Optiflow Nasal High Flow. Intubation was not within the patient's goals of care, so eventually, he decided he wanted to pursue comfort care and passed away surrounded by his family.

KEY POINTS:

- SJS/TEN is a spectrum of potentially life-threatening severe cutaneous adverse reactions. It is a type IV hypersensitivity reaction typically mediated by an immunologic response to a trigger drug¹.
- There should be a low threshold to treat bacterial infections in SJS/TEN because it causes widespread detachment of the skin and mucosa, predisposing patients to superimposed bacterial infections¹.
- As demonstrated in this case, SJS/TEN can lead to multi-organ failure, and having a multidisciplinary approach is essential to providing optimal care.
- In severe cases, Burn Units should be consulted as they can provide unique expertise. Transfer to a Burn Unit can allow for advanced wound care and specialized controlled environments to prevent heat loss, as patients with SJS/TEN lose their skin barrier and cannot regulate their temperature adequately².
- Finally, this case highlights the importance of antibiotic stewardship as the patient had received two courses of cephalexin to treat a non-infectious rash initially, leading to this life-limiting reaction.

Evidence of Conflict of Financial Interest

	Co-author	Conflict disclosures
1	Shaonie Ton-Leclerc	No conflict of interest to disclose.
2	Lourdes Ramirez-Hobak	No conflict of interest to disclose.
3	Marie Leung	No conflict of interest to disclose.

References

- 1. Shah H, Parisi R, Mukherjee E, Phillips EJ, Dodiuk-Gad RP. Update on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management. Am J Clin Dermatol. 2024;25(6):891-908.
- 2. McCullough M, Burg M, Lin E, Peng D, Garner W. Steven Johnson Syndrome and Toxic Epidermal Necrolysis in a burn unit: A 15-year experience. Burns. 2017;43(1):200-5.